BridgeBio Pharma (BBIO) Fundamental Analysis: Revenue, Earnings & Valuation

7.52 / 10

Outperform

Fundamental score 7.5/10 (Outperform). Revenue‑MV and Cash‑MV are strong, PB‑ROE high, and YoY revenue growth exceeds 120%. Weaknesses include negative income‑tax ratio and low Asset‑MV. Overall fundamentals are favorable.

Analysis Checks(7/10)

Revenue-MV

Value-2.19

Score2/3

Weight49.50%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value126.26

Score2/3

Weight-4.87%

1M Return-1.06%

Inventory turnover ratio

Value0.78

Score2/3

Weight-5.67%

1M Return-1.21%

Gross profit margin (%)

Value95.82

Score0/3

Weight-29.52%

1M Return-7.24%

PB-ROE

Value14.48

Score3/3

Weight63.28%

1M Return9.74%

Income tax / Total profit (%)

Value-0.06

Score1/3

Weight-2.33%

1M Return-0.50%

Fixed assets turnover ratio

Value81.13

Score2/3

Weight-2.68%

1M Return-0.51%

Cost of sales ratio (%)

Value4.18

Score2/3

Weight-19.38%

1M Return-4.42%

Asset-MV

Value-0.55

Score0/3

Weight15.84%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight35.84%

1M Return5.94%

Is BBIO undervalued or overvalued?

BBIO scores 7.52/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, -145.98% net margin, -19.86 P/E ratio, -6.93 P/B ratio, and -31.25% earnings growth, these metrics solidify its Outperform investment rating.